Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 1—January 2004

Fluoroquinolones Protective against Cephalosporin Resistance in Gram-negative Nosocomial Pathogens

Mitchell J. Schwaber*1Comments to Author , Sara E. Cosgrove*2, Howard S. Gold*, Keith S. Kaye†, and Yehuda Carmeli*‡
Author affiliations: *Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA; †Duke University Medical Center, Durham, North Carolina, USA; ‡Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Main Article

Table 2

Multivariable analysis of outcomea

Characteristic HR (95% CI)b p
Surgery during risk period 1.62 (1.16 to 2.25) 0.005
In intensive care unit during risk period 2.17 (1.49 to 3.16) <0.001
Receipt of β-lactam/β-lactamase inhibitor 2.52 (1.67 to 3.80) <0.001
Receipt of ureidopenicillin 2.55 (1.43 to 4.53) 0.002
Receipt of 3rd-generation cephalosporin 2.84 (1.89 to 4.27) <0.001
Receipt of fluoroquinolone 0.40 (0.21 to 0.76) 0.005

aOutcome refers to the isolation of third-generation cephalosporin-resistant Enterobacter spp., Pseudomonas aeruginosa, or Klebsiella pneumoniae from a clinical specimen.
bHR, hazard ratio; CI, confidence interval.

Main Article

1Current affiliation: Epidemiology Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

2Current affiliation: Division of Infectious Disease, Johns Hopkins Hospital, Baltimore, Maryland, USA.

Page created: December 21, 2010
Page updated: December 21, 2010
Page reviewed: December 21, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.